Laman UtamaPHIO • NASDAQ
add
Phio Pharmaceuticals Corp
Tutup sebelumnya
$1.17
Julat tahun
$0.81 - $4.19
Permodalan pasaran
13.59J USD
Bilangan Purata
7.43J
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Dis 2025info | Perubahan T/T |
|---|---|---|
Hasil | — | — |
Perbelanjaan pengendalian | 1.06J | 53.41% |
Pendapatan bersih | -2.37J | -45.82% |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | -0.15 | — |
EBITDA | -2.53J | -51.31% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 21.03J | 290.77% |
Jumlah aset | 21.49J | 274.47% |
Jumlah liabiliti | 1.34J | 32.02% |
Jumlah ekuiti | 20.15J | — |
Syer tertunggak | 11.62J | — |
Harga kepada buku | 0.68 | — |
Pulangan pada aset | -38.40% | — |
Pulangan pada modal | -42.25% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -2.37J | -45.82% |
Tunai daripada operasi | -2.08J | -51.64% |
Tunai daripada pelaburan | 0.00 | -100.00% |
Tunai daripada pembiayaan | 12.40J | 815.50% |
Perubahan bersih dalam tunai | 10.33J | 129,175.00% |
Aliran tunai bebas | -1.29J | -64.92% |
Perihal
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Wikipedia
Diasaskan
2011
Tapak web
Pekerja
6
